Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q2)Aug 31, 2025 | (Q1)May 31, 2025 | (FY)Feb 28, 2025 | (Q4)Feb 28, 2025 | (Q3)Nov 30, 2024 | (Q2)Aug 31, 2024 | (Q1)May 31, 2024 | (FY)Feb 29, 2024 | (Q4)Feb 29, 2024 | (Q3)Nov 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 41.27%-150.06K | 86.43%-31.17K | -45.90%-1.29M | -2,835.73%-2.65M | 1,729.09%1.85M | 30.43%-255.51K | 54.26%-229.75K | -275.21%-885.94K | 122.55%97.05K | -137.91%-113.42K |
| Net income from continuing operations | -11.65%-334.56K | 42.36%-271.13K | -129.26%-5.05M | -725.77%-4.46M | 139.20%179.81K | 55.75%-299.65K | 10.91%-470.4K | -51.57%-2.2M | 8.09%-540.55K | -292.29%-458.7K |
| Operating gains losses | 110.52%10.55K | 11.01%33.44K | -94.19%10.07K | -61.48%90.06K | 93.31%-9.88K | -189.51%-100.23K | 221.49%30.12K | 127.27%173.33K | 137.60%233.82K | -1,663.53%-147.68K |
| Depreciation and amortization | 3.14%40.61K | 13.69%44K | -5.61%158.34K | -10.59%40.37K | -8.66%39.88K | -3.57%39.37K | 1.58%38.71K | -23.22%167.75K | -45.88%45.15K | -32.08%43.66K |
| Asset impairment expenditure | ---- | ---- | 8,825.09%4.27M | 50,854.85%4.27M | ---- | ---- | ---- | -72.48%47.82K | -94.70%8.38K | ---- |
| Remuneration paid in stock | -99.11%771 | -96.28%4.15K | -69.03%270.9K | -87.34%31.85K | -82.50%40.89K | -49.19%86.63K | -49.11%111.54K | -32.62%874.82K | -23.10%251.51K | -37.51%233.65K |
| Other non cashItems | -5.49%3.58K | -701.45%-24.55K | -18.34%15.39K | -18.64%4.06K | -18.08%3.46K | -18.59%3.79K | -18.03%4.08K | -0.99%18.85K | -19.63%4.99K | -0.38%4.23K |
| Change In working capital | 784.40%128.99K | 225.49%182.92K | -2,773.33%-961.33K | -2,900.78%-2.63M | 826.55%1.59M | 181.00%14.59K | 126.54%56.2K | -75.07%35.96K | -54.30%93.75K | 608.88%171.98K |
| -Change in receivables | 2,192.61%41.91K | 3,254.55%156.5K | -64,693.24%-755.1K | -12,313.08%-3.15M | 17,727.64%2.4M | 117.93%1.83K | -502.79%-4.96K | 205.13%1.17K | 1,133.76%25.8K | -778.70%-13.61K |
| -Change in prepaid assets | 31.04%24.61K | 142.08%70.64K | -234.83%-38.29K | 3,163.51%687.18K | -11,062.19%-773.43K | 378.79%18.78K | -54.75%29.18K | -80.14%28.4K | -112.87%-22.43K | 74.51%-6.93K |
| -Change in payables and accrued expense | 1,137.41%62.47K | -238.27%-44.22K | -2,727.42%-167.95K | -279.31%-162.06K | -116.54%-31.84K | -461.23%-6.02K | 111.61%31.98K | 171.08%6.39K | 215.05%90.38K | 2,335.21%192.52K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 41.27%-150.06K | 86.43%-31.17K | -45.90%-1.29M | -2,835.73%-2.65M | 1,729.09%1.85M | 30.43%-255.51K | 54.26%-229.75K | -275.21%-885.94K | 122.55%97.05K | -137.91%-113.42K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -140.47%-1.25M | 59.22%-404.83K | 82.55%-1.17M | 170.46%1.29M | 42.43%-940.66K | 68.29%-520.52K | 37.51%-992.83K | 38.72%-6.69M | 44.85%-1.83M | 36.73%-1.63M |
| Net PPE purchase and sale | -3.92%-540.93K | 97.69%-22.89K | 84.38%-1.05M | 177.15%1.41M | 42.43%-940.66K | 68.29%-520.52K | 37.51%-992.83K | 38.72%-6.69M | 44.85%-1.83M | 36.73%-1.63M |
| Net business purchase and sale | ---710.77K | ---381.94K | ---714.89K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net other investing changes | ---- | ---- | --592.73K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -140.47%-1.25M | 59.22%-404.83K | 82.55%-1.17M | 170.46%1.29M | 42.43%-940.66K | 68.29%-520.52K | 37.51%-992.83K | 38.72%-6.69M | 44.85%-1.83M | 36.73%-1.63M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -38.52%641.87K | 1,877.97%590.86K | -32.06%953.63K | 76.84%-25.63K | -6,698.54%-31.54K | -29.48%1.04M | -199.21%-33.23K | -88.03%1.4M | -237.46%-110.69K | 100.75%478 |
| Net issuance payments of debt | -21.81%-36.04K | -11.77%-37.14K | 15.26%-119.99K | 76.84%-25.63K | -6,698.54%-31.54K | -1,766.87%-29.59K | -0.19%-33.23K | -19.55%-141.6K | -237.46%-110.69K | 100.90%478 |
| Net common stock issuance | ---- | ---- | -29.13%1.1M | --0 | --0 | -25.93%1.1M | --0 | -87.04%1.55M | --0 | --0 |
| Net other financing activities | ---655.09K | --628K | -1,928.47%-22.37K | --0 | --0 | ---- | ---- | 98.80%-1.1K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -38.52%641.87K | 1,877.97%590.86K | -32.06%953.63K | 76.84%-25.63K | -6,698.54%-31.54K | -29.48%1.04M | -199.21%-33.23K | -88.03%1.4M | -237.46%-110.69K | 100.75%478 |
| Net cash flow | ||||||||||
| Beginning cash position | -8.05%3.22M | -34.80%3.09M | -56.60%4.73M | -29.78%4.62M | -54.95%3.75M | -60.47%3.5M | -56.60%4.73M | 12.57%10.91M | -53.15%6.57M | -49.20%8.32M |
| Current changes in cash | -383.53%-759.9K | 112.33%154.85K | 75.60%-1.51M | 24.23%-1.39M | 150.12%875.46K | 150.73%268.01K | 38.97%-1.26M | -1,184.88%-6.17M | 51.25%-1.84M | 25.57%-1.75M |
| Effect of exchange rate changes | 34.05%-11.37K | -233.76%-25.55K | -6,872.00%-141.18K | -13,539,800.00%-135.4K | ---7.65K | ---17.24K | 1,043.77%19.1K | -100.31%-2.03K | -100.00%-1 | --0 |
| End cash Position | -34.77%2.45M | -8.05%3.22M | -34.80%3.09M | -34.80%3.09M | -29.78%4.62M | -54.95%3.75M | -60.47%3.5M | -56.60%4.73M | -56.60%4.73M | -53.15%6.57M |
| Free cash from | 10.96%-690.99K | 95.58%-54.06K | 69.14%-2.34M | 27.92%-1.25M | 151.91%907K | 61.37%-776.03K | 41.54%-1.22M | 32.07%-7.58M | 53.78%-1.73M | 23.48%-1.75M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.